This acquisition will help Sandoz to build on its current portfolio of respiratory medicines and boost patient access to complex treatments
Image: The burden of respiratory diseases on healthcare systems and productivity crossed over $380bn annually across 28 EU member states. (Credit: Towfiqu barbhuiya on Unsplash)
Sandoz, a Novartis division, has acquired Coalesce Product Development Limited, a UK-based medical and drug delivery device development company.
With this transaction, Sandoz has acquired the capabilities and assets of Coalesce, which in turn will help the Novartis unit to build on its current portfolio of respiratory medicines and further boost patient access to complex treatments.
Sandoz CEO, Richard Saynor said: “Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity.
“At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients.”
A major non-communicable disease, Asthma impacts both children and adults. In 2019, it is estimated to have affected 262 million people. The same year had recorded around 3.23 million deaths due to chronic obstructive pulmonary disease (COPD). The burden of respiratory diseases on healthcare systems and productivity crossed over $380bn annually across 28 EU member states.
With a current portfolio of six in market-products and almost twice as many more products in the pipeline, Sandoz considers respiratory as an important aspect of its long-term growth strategy and plans to explore more opportunities both in-house and externally.
Sandoz also plans to expand its portfolio in the complex generics area, including complex injectables.